

Poster of Distinction

Poster Viewing Session 1

Thursday, 12.09.2019 · 12:50 – 13:50 h

Chairs: Raanan Shamir (Israel) · Kaija-Leena Kolho (Finland)

P-001	<i>Ju Whi Kim, Republic of Korea</i>
	GM-CSF producing NCR- ILC3s directly activate neutrophils in the intestinal mucosa of inflammatory bowel disease
P-002	<i>Johan Van Limbergen, The Netherlands</i>
	Shifts in bacterial community function are associated with Short Chain Fatty Acid (SCFA) pathways during nutritional therapy in paediatric Crohn's disease patients
P-004	<i>Sara Sila, Croatia</i>
	Altered intestinal microbiota is present in newly diagnosed IBD patients and significantly differs from that of healthy siblings and healthy controls
P-006	<i>Eytan Wine, Canada</i>
	Increased faecal short chain fatty acid content with Infliximab therapy in paediatric crohn disease
P-009	<i>Corentin Babakissa, Canada</i>
	IL-17-related signature genes are linked to human necrotizing enterocolitis
P-014	<i>Ola Olén, Sweden</i>
	Paediatric inflammatory bowel diseases and risk of serious infections: A nationwide register-based cohort study
P-017	<i>Ilona Csizmadia, Ireland</i>
	Risk factors for developing paediatric inflammatory bowel disease in an Irish prospective cohort
P-020	<i>Tatsuki Mizuochi, Japan</i>
	Diagnostic accuracy of serum proteinase 3 antineutrophil cytoplasmic antibodies for paediatric patients with ulcerative colitis: a prospective multicenter study in Japan
P-025	<i>Gili Focht, Israel</i>
	The newly simplified MaRIA score (MaRIAs) is as accurate as the original MaRIA in paediatric Crohn's Disease: a study from the ImageKids cohort
P-033	<i>Valeria Dipasquale, Italy</i>
	Pouchitis in pediatric ulcerative colitis: a multicenter study on behalf of Italian society of pediatric gastroenterology, hepatology and nutrition

Poster Viewing Session 2

Friday, 13.09.2019 · 13:00 – 13:50 h

Chairs: Sanja Kolaček (Croatia) · Sibylle Koletzko (Germany)

P-047	<i>Lucia Cococcioni, United Kingdom</i>
	Safety and efficacy of ferric carboxymaltose [FCM] for the treatment of iron deficiency anaemia in paediatric patients affected by inflammatory bowel disease (pIBD)
P-052	<i>Thomas Walters, Canada</i>
	Exclusive enteral nutrition versus corticosteroid induction therapy for new onset paediatric Crohn's disease: comparison of 18 month outcomes in a Canadian prospective multi-centre inception cohort
P-066	<i>Ryma Iratni, Canada</i>
	Trends in TNF-alpha inhibitor utilization in children with IBD during the last 10 years: 2009 – 2018
P-068	<i>Maria Myrthe Elisabeth Jongmsa, The Netherlands</i>
	Infliximab in young pediatric IBD patients: it is all about the dosing – a multicenter study from the pediatric IBD Porto group of ESPGHAN
P-071	<i>Ben Kang, Republic of Korea</i>
	Infliximab trough levels are not associated with transmural healing at 1 year treatment in paediatric Crohn's disease patients
P-076	<i>Alexandra Petrova, Canada</i>
	Infliximab clearance at and post induction predicts clinical and endoscopic outcomes at 1 year in children with Crohn's disease treated with Infliximab
P-103	<i>Patrick van Rheenen, The Netherlands</i>
	Time-to-reach target calprotectin level and relation with first relapse in newly diagnosed patients with IBD: first results of the Fast Forward Care Prospective Registry
P-110	<i>Martha. A.C van Gaalen, The Netherlands</i>
	Transition test is a valid tool to monitor disease knowledge in adolescents with IBD transitioning to adult care